The global fight against cancer cannot be fully achieved without a strong commitment to improving the efficiency and quality of cancer care provided to patients and people affected by cancer worldwide. To support this, All.Can International has developed the Action Guide For Efficient Cancer Care, designed to offer actionable insights and practical guidance for the implementation of cancer care efficiency metrics across health systems.
Efficiency in cancer care is not just about cost reduction; it is about delivering the best possible health outcomes by optimising the use of available resources—be they human, financial, infrastructural, or technological. All.Can defines efficiency as care that prioritises what truly matters to patients and society, shifting the focus from mere process and volume to the health outcomes that truly reflect the success of a health system.
In this context, the measurement and monitoring of cancer care efficiency become indispensable. By broadening the data we collect—especially through cancer-specific indicators and patient-reported outcomes—we can ensure that health systems are geared toward improving population health in a person-centered manner. This approach must become a routine part of the decision-making process across the entire cancer care ecosystem, supporting the delivery of high-quality, efficient care.
This Action Guide was produced on behalf of, and in close collaboration with, All.Can International by a research team from the Health Care Systems and Services research unit in the Department of Public and Occupational Health at Amsterdam UMC, University of Amsterdam, Netherlands:
- Dr Ana Sofia Carvalho, MD MScPH PhD candidate
- Dr Damir Ivanković, MD MBA PhD
- Dr Erica Barbazza, PhD
- Dr Óscar Brito Fernandes, PhD
- Professor Niek Klazinga, MD PhD
- Dr Dionne Kringos, PhD
All.Can work is made possible with public and private funds. Support for this publication has been received from Amgen, Astellas, Becton Dickinson, Bristol Myers Squibb, Illumina, Johnson & Johnson, MNI, MSD and Roche.